文献速递痛风与晶体性关节病自身炎症与 IgG4 相关病

IL-37罕见遗传变异链接抗炎细胞因子与痛风发病及治疗

Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout.
PubMed 文献 · Ann Rheum Dis · 2020-02-29

研究对痛风患者和健康对照进行IL37基因测序,发现四个罕见变异仅存在于痛风患者中且聚集于外显子5功能域,预测模型和功能实验证实这些变异导致抗炎功能丧失,重组IL-37在体外和痛风小鼠模型中显示治疗潜力,p.(N182S)携带状态与波利尼西亚裔高尿酸血症个体痛风风险增加相关。

要点

  • IL37罕见变异仅见于痛风患者,聚集于外显子5功能域并导致抗炎功能丧失。
  • 重组IL-37在体外和痛风小鼠模型中显示治疗痛风性炎症的潜力。
  • p.(N182S)携带状态与波利尼西亚裔高尿酸血症个体痛风风险增加相关。

核心结论

  • IL-37罕见功能丧失变异与痛风发病相关,重组IL-37具有治疗痛风性关节炎的潜力。

研究设计与样本

  • 发现队列对痛风675例和对照520例进行IL37全部编码区DNA测序,验证队列对痛风2202例和对照2295例进行TaqMan基因分型。
  • 对罕见变异进行蛋白质结构预测建模,随后体外实验评估对蛋白功能的影响。
  • 在体外和痛风小鼠模型中评估重组IL-37治疗。

主要发现

  • 在6例发现队列痛风患者中鉴定出四个IL37罕见变异:p.(A144P)、p.(G174Dfs*16)、p.(C181*)和p.(N182S),健康对照中未出现(Fisher精确检验p值=0.043)。
  • 所有变异聚集于IL-37外显子5的功能域(p值=5.71×10-5)。
  • 预测建模和功能研究证实抗炎功能丧失。
  • p.(N182S)(rs752113534)携带状态与波利尼西亚裔高尿酸血症个体痛风风险增加相关(OR=1.81,p值=0.031)。

关键数值与推荐

  • 发现队列:痛风n=675,对照n=520;验证队列:痛风n=2202,对照n=2295。
  • 四个罕见变异仅见于6例发现队列痛风患者,健康对照中无(Fisher精确检验p值=0.043)。
  • 变异聚集于外显子5功能域(p值=5.71×10-5)。
  • p.(N182S)(rs752113534)携带者痛风风险OR=1.81,p值=0.031。

临床怎么用

  • IL-37功能丧失变异可能作为痛风遗传易感标志,尤其在高尿酸血症人群中。
  • 重组IL-37代表痛风性关节炎的潜在治疗方向,尚需临床验证。

局限性

  • 罕见变异发现基于较小发现队列,需更大样本验证。
  • 重组IL-37疗效仅在体外和 mouse 模型中评估,尚未在人体验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Gout is characterised by severe interleukin (IL)-1-mediated joint inflammation induced by monosodium urate crystals. Since IL-37 is a pivotal anti-inflammatory cytokine suppressing the activity of IL-1, we conducted genetic and functional studies aimed at elucidating the role of IL-37 in the pathogenesis and treatment of gout. METHODS: Variant identification was performed by DNA sequencing of all coding bases of IL37 using molecular inversion probe-based resequencing (discovery cohort: gout n=675, controls n=520) and TaqMan genotyping (validation cohort: gout n=2202, controls n=2295). Predictive modelling of the effects of rare variants on protein structure was followed by in vitro experiments evaluating the impact on protein function. Treatment with recombinant IL-37 was evaluated in vitro and in vivo in a mouse model of gout. RESULTS: We identified four rare variants in IL37 in six of the discovery gout patients; p.(A144P), p.(G174Dfs*16), p.(C181*) and p.(N182S), whereas none emerged in healthy controls (Fisher's exact p-value=0.043). All variants clustered in the functional domain of IL-37 in exon 5 (p-value=5.71×10-5). Predictive modelling and functional studies confirmed loss of anti-inflammatory functions and we substantiated the therapeutic potential of recombinant IL-37 in the treatment of gouty inflammation. Furthermore, the carrier status of p.(N182S)(rs752113534) was associated with increased risk (OR=1.81, p-value=0.031) of developing gout in hyperuricaemic individuals of Polynesian ancestry. CONCLUSION: Here, we provide genetic as well as mechanistic evidence for the role of IL-37 in the pathogenesis of gout, and highlight the therapeutic potential of recombinant IL-37 for the treatment of gouty arthritis.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Klück V, van Deuren RC, Cavalli G, et al. Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout. Ann Rheum Dis. 2020. PMID: 32114511. doi:10.1136/annrheumdis-2019-216233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。